Vasopeptidase inhibitors: a new class of dual zinc metallopeptidase inhibitors for cardiorenal therapeutics.
Vasopeptidase inhibitors are a new class of drugs that simultaneously inhibit angiotensin-I-converting enzyme and neutral endopeptidase 24.11, two metallopeptidases responsible for the breakdown of different vasoactive peptides. At least ten vasopeptidase inhibitors are in various stages of development and results obtained in preclinical and clinical studies indicate a promising future for the treatment of hypertension, heart failure and renal disease. However, like angiotensin-I-converting-enzyme inhibitors, vasopeptidase inhibitors are characterized by acute and chronic side-effects that need to be clarified.
Molinaro
Giuseppe
G
Faculté de Pharmacie, Université de Montréal, Montréal, Québec, H3C 3J7, Canada.
Rouleau
Jean-Lucien
JL
Adam
Albert
A
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000201:enzymology; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D006801:Humans; D007674:Kidney Diseases / Q000188:drug therapy* / Q000201:enzymology; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015260:Neprilysin / Q000037:antagonists & inhibitors*; D011480:Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D015032:Zinc / Q000378:metabolism
D000806:Angiotensin-Converting Enzyme Inhibitors; D011480:Protease Inhibitors; D008666:Metalloendopeptidases; D015260:Neprilysin; D015032:Zinc